

DAFTAR PUSTAKA

Bai, R., Du, J., Lv, S., Hua, W., Dai, L. and Wu, H. (2022) ‘Benefits and Risks of Rapid Initiation of Antiretroviral Therapy: A Systematic Review and Meta-Analysis’, *Frontiers in Pharmacology*, 13(June), pp. 1–12. Available at: <https://doi.org/10.3389/fphar.2022.898449>.

Bishop, J.D., DeShields, S., Cunningham, T. and Troy, S.B. (2016) ‘CD4 Count Recovery After Initiation of Antiretroviral Therapy in Patients Infected With Human Immunodeficiency Virus’, *American Journal of the Medical Sciences*, 352(3), pp. 239–244. Available at: <https://doi.org/10.1016/j.amjms.2016.05.032>.

CDC (2024a) *HIV Risk and Prevention Estimates*. Available at: <https://www.cdc.gov/hivpartners/php/riskandprevention/index.html#:~:text=There are now more options,can all effectively reduce risk>.

CDC (2024b) *Preventing HIV with PrEP, HIV*. Available at: <https://www.cdc.gov/hiv/prevention/prep.html#:~:text=PrEP is for adults and,to your health care provider>.

Dah, T.T.E., Yaya, I., Mensah, E., Coulibaly, A., Kouamé, J.B.M., Traoré, I., *et al.* (2021) ‘Rapid antiretroviral therapy initiation and its effect on treatment response in MSM in West Africa’, *Aids*, 35(13), pp. 2201–2210. Available at: <https://doi.org/10.1097/QAD.0000000000003046>.

Darraj, M. *et al.* (2018) “Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression,” *Journal of Infection and Public Health*, 11(2), pp. 265–269. Available at: <https://doi.org/10.1016/j.jiph.2017.08.001>.

Ding, Y., Duan, S., Wu, Z., Ye, R., Yang, Y., Yao, S., *et al.* (2016) ‘Timing of antiretroviral therapy initiation after diagnosis of recent human immunodeficiency virus infection and CD4+ T-cell recovery’, *Clinical Microbiology and Infection*, 22(3),

pp. 290.e5-290.e8. Available at: <https://doi.org/10.1016/j.cmi.2015.11.007>.

Dirjen P2P (2022) 'Laporan Perkembangan HIV-AIDS dan Penyakit Infeksi Menular Seksual (PIMS) Triwulan 1 2022', *Kemenkes* [Preprint].

Garcia, S.A.B. and Guzman, N. (2023) *Acquired Immune Deficiency Syndrome CD4+ Count*, *StatPearls* [Internet]. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK513289/>.

Ge, Y., Zhou, Y., Liu, Y., Lu, J., Qiu, T., Shi, L.E., *et al.* (2023) 'Immune reconstitution efficacy after combination antiretroviral therapy in male HIV-1 infected patients with homosexual and heterosexual transmission', *Emerging Microbes and Infections*, 12(1). Available at: <https://doi.org/10.1080/22221751.2023.2214250>.

Gezie, L.D. (2016) 'Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: Multilevel analysis', *BMC Research Notes*, 9(1), pp. 1–9. Available at: <https://doi.org/10.1186/s13104-016-2182-4>.

Gwadu, A.A. and Tegegne, A.S. (2022) 'Determinants of CD4 count and risk for death of HIV infected children under ART', *Scientific Reports*, 12(1), pp. 1–7. Available at: <https://doi.org/10.1038/s41598-022-10880-y>.

Handoko, R., Colby, D.J., Kroon, E., Sacdalan, C., de Souza, M., Pinyakorn, S., *et al.* (2020) 'Determinants of suboptimal CD4+ T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV-1 infection', *Journal of the International AIDS Society*, 23(9), pp. 1–9. Available at: <https://doi.org/10.1002/jia2.25585>.

Holden, C.J., Lampe, F.C., Burns, F.M., Chaloner, C., Johnson, M., Kinloch-De Loes, S., *et al.* (2024) 'Association of age at antiretroviral therapy initiation with CD4+:CD8+ratio recovery among virally suppressed people with HIV', *Aids*, 38(5), pp. 703–711. Available at: <https://doi.org/10.1097/QAD.0000000000003801>.

Huang, Y.C., Sun, H.Y., Chuang, Y.C., Huang, Y.S., Lin, K.Y., Huang, S.H., *et al.* (2019) ‘Short-term outcomes of rapid initiation of antiretroviral therapy among HIV-positive patients: Real-world experience from a single-centre retrospective cohort in Taiwan’, *BMJ Open*, 9(9), pp. 1–8. Available at: <https://doi.org/10.1136/bmjopen-2019-033246>.

IAPAC (2024) *Antiretroviral Therapy (ART)*. Available at: [https://doi.org/10.1016/0738-081X\(91\)90111-W](https://doi.org/10.1016/0738-081X(91)90111-W).

Jiang, J., Qin, X., Liu, H., Meng, S., Abdullah, A.S., Huang, Jinping, *et al.* (2019) ‘An optimal BMI range associated with a lower risk of mortality among HIV-infected adults initiating antiretroviral therapy in Guangxi, China’, *Scientific Reports*, 9(1), pp. 1–10. Available at: <https://doi.org/10.1038/s41598-019-44279-z>.

Joint United Nations Programme on HIV/AIDS (UNAIDS) (2024) ‘Fact sheet 2024 - Latest global and regional HIV statistics on the status of the AIDS epidemic’. Available at: <https://www.unaids.org/en>.

Katirayi, L., Maphosa, T., Chilikutali, L., Chamanga, R.K., Petersson, J., Khatib, S., *et al.* (2023) ‘Understanding gender differences of people with HIV newly diagnosed or returning to care with advanced HIV disease in Malawi: a qualitative study’, *BMC Public Health*, 23(1), pp. 1–10. Available at: <https://doi.org/10.1186/s12889-023-17384-y>.

Kementerian Kesehatan Republik Indonesia (2014) ‘Peraturan Menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2004 Tentang Pedoman Antiretroviral’, *Kementerian Kesehatan Republik Indonesia*, pp. 75–76. Available at: https://siha.kemkes.go.id/portal/files_upload/Buku_Permenkes_ARV_Cetak.pdf.

Le, T., Wright, E.J., Smith, D.M., He, W., Catano, G., Okulicz, J.F., *et al.* (2013) ‘Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy’, 368(3), pp. 218–230. Available at: <https://doi.org/10.1056/NEJMoa1110187>.Enhanced.

Lembas, A., Załęski, A., Mikuła, T., Dyda, T., Stańczak, W. and Wiercińska-Drapało, A. (2022) ‘Evaluation of Clinical Biomarkers Related to CD4 Recovery in HIV-Infected Patients—5-Year Observation’, *Viruses*, 14(10), pp. 1–20. Available at: <https://doi.org/10.3390/v14102287>.

Lundgren, J.D., Babiker, A.G., Sharma, S., Grund, B., Philips, A.N. and Matthew, G. (2018) ‘Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection’, *Physiology & behavior*, 176(5), pp. 139–148. Available at: <https://doi.org/10.4049/jimmunol.1801473>.The.

Mashiri, C.E. *et al.* (2024) “Investigating the Determinants of Mortality before CD4 Count Recovery in a Cohort of Patients Initiated on Antiretroviral Therapy in South Africa Using a Fine and Gray Competing Risks Model,” *Tropical Medicine and Infectious Disease*, 9(7). Available at: <https://doi.org/10.3390/tropicalmed9070154>.

Maskew, M., Brennan, A.T., Westreich, D., McNamara, L., MacPhail, A.P. and Fox, M.P. (2013) ‘Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients’, *Journal of Women’s Health*, 22(2), pp. 113–120. Available at: <https://doi.org/10.1089/jwh.2012.3585>.

Maurya, S.P., Singh, R., Negi, N., Kapil, A., Chaudhry, R. and Das, B.K. (2016) ‘The level of education affects CD4 cell count and wellness among HIV infected adult between age group 18 to 60 years’, *International Journal of Infectious Diseases*, 45(1), p. 264. Available at: <https://doi.org/https://doi.org/10.1016/j.ijid.2016.02.589>.

May, M.T., Gompels, M., Delpech, V., Porter, K., Orkin, C., Kegg, S., *et al.* (2014) ‘Impact on life expectancy of HIV-1 positive individuals of CD4R cell count and viral load response to antiretroviral therapy’, *Aids*, 28(8), pp. 1193–1202. Available at: <https://doi.org/10.1097/QAD.0000000000000243>.

Nugroho, E., Novanda, A., Utami, M., Nirmala, E.D., Yuswantoro, R.N. and Janah, S.U. (2023) ‘Social Determinants of HIV/AIDS: a Public Health Perspective’, *Journal*

of Health Education, 8(2), pp. 99–107. Available at:
<https://journal.unnes.ac.id/sju/jhealhedu/article/view/62855>.

Pemerintah Kota Yogyakarta (2023) *Deteksi Dini HIV/AIDS Harapan Hidup Penderita Makin Tinggi*, *Portal Berita Pemerintah Kota Yogyakarta*. Available at:
<https://warta.jogjakota.go.id/detail/index/30438>.

Risher, K.A., Cori, A., Reniers, G., Marston, M., Calvert, C., Crampin, A., *et al.* (2021) ‘Age patterns of HIV incidence in eastern and southern Africa: a modelling analysis of observational population-based cohort studies’, *The Lancet HIV*, 8(7), pp. e429–e439. Available at: [https://doi.org/10.1016/S2352-3018\(21\)00069-2](https://doi.org/10.1016/S2352-3018(21)00069-2).

Sajadipour, M., Rezaei, S., Irandoost, S.F., Ghaumzadeh, M., Salmani nadushan, M., Gholami, M., *et al.* (2022) ‘What explains gender inequality in HIV infection among high-risk people? A Blinder-Oaxaca decomposition’, *Archives of Public Health*, 80(1), pp. 1–9. Available at: <https://doi.org/10.1186/s13690-021-00758-2>.

Saputro, F.A. and Ramadhan, B. (2023) *188 Kasus HIV Baru di Sleman Yogyakarta, Dinkes: 41 Sudah Stadium 4, Republika*. Available at:
<https://news.republika.co.id/berita/s1e85r330/188-kasus-hiv-baru-di-sleman-yogyakarta-dinkes-41-sudah-stadium-4>.

Shushtari, Z.J., Sajjadi, H., Forouzan, A.S., Salimi, Y. and Dejman, M. (2014) ‘Disclosure of HIV status and social support among people living with HIV’, *Iranian Red Crescent Medical Journal*, 16(8). Available at:
<https://doi.org/10.5812/ircmj.11856>.

Thomadakis, C., Yiannoutsos, C.T., Pantazis, N., Diero, L., Mwangi, A., Musick, B.S., *et al.* (2023) ‘The Effect of HIV Treatment Interruption on Subsequent Immunological Response’, *American Journal of Epidemiology*, 192(7), pp. 1181–1191. Available at:
<https://doi.org/10.1093/aje/kwad076>.

UNAIDS (2024) ‘Undetectable = Untransmittable: Public Health and HIV Viral Load

Suppression’, *UNAIDS Explainer*, (July), pp. 1–4. Available at: <https://www.unaids.org/en/resources/documents/2018/undetectable-untransmittable>.

Vaillant, A.A.J. and Naik, R. (2023) *HIV-1 Associated Opportunistic Infections, StatPearls [Internet]*. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK539787/>.

WHO (2016) ‘The use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach second edition’, *World Health Organisation (WHO)*, Guidelines, p. Annex 1.

WHO (2021) *Guidelines HIV prevention, testing, treatment, service delivery and monitoring: Recommendation for public health approach*.

WHO (2024a) *HIV, Health Topics*. Available at: https://www.who.int/health-topics/hiv-aids#tab=tab_1.

WHO (2024b) *HIV and AIDS, Fact sheets*. Available at: [https://www.who.int/news-room/fact-sheets/detail/hiv-aids#:~:text=HIV is spread from the,with antiretroviral therapy \(ART\)](https://www.who.int/news-room/fact-sheets/detail/hiv-aids#:~:text=HIV is spread from the,with antiretroviral therapy (ART)).

WHO (2024c) ‘HIV statistics, globally and by WHO region, 2024’, pp. 1–8. Available at: <https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics>.

Yildirim, F.S., Candevir, A., Akhan, S., Kaya, S., Çabalak, M., Ersöz, G., *et al.* (2023) ‘Comparison of Immunological and Virological Recovery with Rapid, Early, and Late Start of Antiretroviral Treatment in Naive Plwh: Real-World Data’, *International Journal of General Medicine*, 16(April), pp. 1867–1877. Available at: <https://doi.org/10.2147/IJGM.S393370>.

Zhu, J., Huang, H., Wang, M., Zhang, Y., Mo, J., Tian, W., *et al.* (2022) ‘High baseline body mass index predicts recovery of CD4+ T lymphocytes for HIV/AIDS patients

receiving long-term antiviral therapy', *PLoS ONE*, 17(12 December), pp. 1–18.

Available at: <https://doi.org/10.1371/journal.pone.0279731>.